Clinical trial NCT01663389: A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose
Official title: An Open Label, Non-Randomized, Single Dose, Two Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Infections, Bacterial
Keywords: mass balance
radiolabel
oral
IV
GSK1322322
healthy volunteer
antibiotic
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2012-08-13
Enrollment: 5
Sex: MALE
Minimum age (years): 30
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is a phase 1, non-randomized, open label, single-dose, two-period, cross-over study. This study will utilize 14C radiolabeled GSK1322322 to investigate the recovery, excretion, and pharmacokinetics of GSK1322322 in 6 healthy adult male subjects through the sampling of blood, urine, and feces.

Each subject will participate in the study for approximately 7 to 8 weeks i.e., 30 day screening period, two dosing periods (approximately 8 days each) and a follow up visit.

The subjects will be admitted to the clinical unit on Day 1 of the first treatment period and remain in the unit for up to approximately 16 days through the end of the second treatment period.

On Day 1 of Period 1, each subject will receive 14C radiolabeled GSK1322322 as a single therapeutic intravenous (IV) dose (1000 milligrams \[mg\]). When the total radioactivity is \<1% of the administered dose in all subjects, Period 2 dosing will begin (approximately 8 days after the IV dose). On Day 1 of Period 2, each subject will receive single therapeutic oral solution dose (1200 mg). Blood, urine, bile and fecal samples will be collected during both the periods. The subject may be discharged from the unit as early as Day 8 of Period 2. Subjects will visit the study unit for the follow-up visit 7 to 10 days following discharge from the unit.


Eligibility criteria: Inclusion Criteria:

* Healthy male subjects between 30 and 55 years of age, with body weight between 60 to 80 kilograms (kg) and a history of regular bowel movements
* Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods from first dose of study medication until the final follow up visit
* Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin =\<1.5x upper limit of normal
* QT interval by Bazett's correction formula (QTcB) \<450 millisecond (msec); or QTcB \<480 msec in subjects with Bundle Branch Block
* Available to complete the study and return for follow-up visits if necessary
* Capable of giving written informed consent

Exclusion Criteria:

* Any condition that could interfere with the accurate assessment and recovery of radioactivity \[14C\]
* Participation in a clinical trial involving administration of radiolabeled 14C-labelled compound(s) within the last 12 months
* Any condition which impairs the absorption, distribution, metabolism or excretion of the investigational product
* Subjects with a history of cholecystectomy
* Subject has received a total body radiation dose of greater than 5.0 millisievert (mSv) or exposure to significant radiation during 1 year before dosing
* The subject has a positive: drug/alcohol, Hepatitis, HIV screen
* Abuse of alcohol
* History of liver disease, or known hepatic or biliary abnormalities
* The subject has recently received an investigational product
* Donation of more than 500 mL blood within a 56 day period
* Unwillingness or inability to follow the procedures outlined in the protocol
* Use of prescription or non-prescription drugs
* Subject is mentally or legally incapacitated
* History of sensitivity to heparin or heparin-induced thrombocytopenia
* Smoking or history or regular use of tobacco or nicotine-containing products
* Unable to refrain from consumption of red wine, Seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose
* History of cardiac disease

Primary outcomes:
measure: Plasma pharmacokinetic (PK) parameters of GSK1322322 and radiolabeled compound following single IV or oral solution dose: AUC(0-infinity), AUC(0-t), Cmax, tmax, t1/2 for IV and oral solution regimens and CL and Vss for IV regimen only
timeFrame: Day 1 through Day 8 of Period 1 and Period 2 (16 days)
measure: Percent total recovery of radioactivity in urine and feces in each interval and cumulative
timeFrame: Day 1 through Day 8 (and additional days, if required) of Period 1 and Period 2 (16 days or more)
Secondary outcomes:
measure: Safety parameters including adverse events, clinical laboratory tests, concomitant medications, electrocardiograms, and vital signs
timeFrame: Duration of the study (56 days)
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: GSK Investigational Site
state: Minnesota
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: